Ixabepilone Contents History Pharmacology Approval Clinical uses References External links Navigation menuMonographa608042IxabepiloneWHO219989-84-164455406824DB0484520145579K27005NP0AD04645ChEMBL1201752100.158.736Interactive image(verify)"Novel cytotoxic agents: epothilones"10.2146/ajhp0800891846332710.1007/s00280-008-0724-81834779510.1007/s00280-015-2863-z26416565"Ixabepilone for the treatment of solid tumors: a review of clinical data"10.1517/13543784.17.3.42318321240"Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer"10.2146/ajhp0706281894586010.1586/14737140.8.6.99318533808Medical News Today"Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment"10.1200/JCO.2007.12.655717968020"Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas"10.1200/JCO.2006.08.730417261851Ixempra product websiteIxempra prescribing informatione

Vinca alkaloidsVinblastineVincristineVinflunineVindesineVinorelbineTaxanesCabazitaxelDocetaxelLarotaxelOrtataxelPaclitaxelTesetaxelEpothilonesIxabepiloneDihydrofolate reductase inhibitorAminopterinMethotrexatePemetrexedPralatrexateThymidylate synthase inhibitorRaltitrexedPemetrexedAdenosine deaminase inhibitorPentostatinHalogenatedribonucleotide reductase inhibitorsCladribineClofarabineFludarabineNelarabineThiopurineTioguanineMercaptopurineThymidylate synthase inhibitorFluorouracilCapecitabineDoxifluridineTegafur+gimeracil/oteracilCarmofurFloxuridineDNA polymerase inhibitorCytarabineRibonucleotide reductase inhibitorGemcitabineHypomethylating agentAzacitidineDecitabineRibonucleotide reductase inhibitorHydroxycarbamideCamptothecaCamptothecinCositecanBelotecanGimatecanExatecanIrinotecanLurtotecanSilatecanTopotecanRubitecanPodophyllumEtoposideTeniposideAnthracyclinesAclarubicinDaunorubicinDoxorubicinEpirubicinIdarubicinAmrubicinPirarubicinValrubicinZorubicinAnthracenedionesMitoxantronePixantroneNitrogen mustardsChlormethineCyclophosphamideIfosfamideTrofosfamideChlorambucilMelphalanPrednimustineBendamustineUramustineNitrosoureasCarmustineLomustineSemustineFotemustineNimustineRanimustineStreptozocinAlkyl sulfonatesBusulfanMannosulfanTreosulfanAziridinesCarboquoneThiotepaTriaziquoneTriethylenemelamineCarboplatinCisplatinDicycloplatinNedaplatinOxaliplatinSatraplatinHydrazinesProcarbazineTriazenesDacarbazineTemozolomideAltretamineMitobronitolPipobromanStreptomycesActinomycinBleomycinMitomycinsPlicamycinFITipifarnibCDKinhibitorsAbemaciclibAlvocidibPalbociclibRibociclibSeliciclibPrIBortezomibCarfilzomibIxazomibPhIAnagrelideIMPDITiazofurinLIMasoprocolPARP inhibitorNiraparibOlaparibRucaparibHDACBelinostatPanobinostatRomidepsinVorinostatPIKIIdelalisibERAAtrasentanRetinoid X receptorBexaroteneSex steroidTestolactoneAmsacrineTrabectedinRetinoidsAlitretinoinTretinoinArsenic trioxideAsparagine depletersAsparaginasePegaspargaseCelecoxibDemecolcineElesclomolElsamitrucinEstramustine phosphateEtoglucidLonidamineLucanthoneMitoguazoneMitotaneOblimersenOmacetaxine mepesuccinateEribulin


Bristol-Myers SquibbMitotic inhibitorsThiazolesEpoxidesLactams


INNBristol-Myers Squibbchemotherapeuticsemi-syntheticanalogepothilonemetabolic stabilitypharmacokineticsmedicinal chemistryTaxolmicrotubulesFood and Drug Administrationmetastaticbreast cancerEMEAcapecitabineanthracyclinetaxanenon-Hodgkin's lymphoma
























































Ixabepilone (INN; also known as azaepothilone B, codenamed BMS-247550) is a pharmaceutical drug developed by Bristol-Myers Squibb as a chemotherapeutic medication for cancer.[1]




Contents





  • 1 History


  • 2 Pharmacology


  • 3 Approval


  • 4 Clinical uses


  • 5 References


  • 6 External links




History


Ixabepilone is a semi-synthetic analog of epothilone B, a natural chemical compound produced by Sorangium cellulosum.[2] Epothilone B itself could not be developed as a pharmaceutical drug because of poor metabolic stability and pharmacokinetics.[3] Ixabepilone was designed through medicinal chemistry to improve upon these properties.[3]



Pharmacology


Much like Taxol, Ixabepilone acts to stabilize microtubules.[4][5][6]
It is highly potent, capable of damaging cancer cells in very low concentrations, and retains activity in cases where tumor cells are insensitive to taxane type drugs.[7]



Approval


On October 16, 2007, the U.S. Food and Drug Administration approved ixabepilone for the treatment of aggressive metastatic or locally advanced breast cancer no longer responding to currently available chemotherapies.[8] In November 2008, the EMEA has refused a marketing authorisation for Ixabepilone.[9]


Ixabepilone is administered through injection, and is marketed under the trade name Ixempra.



Clinical uses


Ixabepilone, in combination with capecitabine, has demonstrated effectiveness in the treatment of metastatic or locally advanced breast cancer in patients after failure of an anthracycline and a taxane.[10]


It has been investigated for use in treatment of non-Hodgkin's lymphoma.[11]
In pancreatic cancer phase two trial it showed some promising results (used alone). Combination therapy trials are ongoing.[7]



References




  1. ^ http://www.cancer.org/Treatment/TreatmentsandSideEffects/GuidetoCancerDrugs/Ixabepilone


  2. ^ Goodin S (May 2008). "Novel cytotoxic agents: epothilones". Am J Health Syst Pharm. 65 (10 Suppl 3): S10–5. doi:10.2146/ajhp080089. PMID 18463327..mw-parser-output cite.citationfont-style:inherit.mw-parser-output .citation qquotes:"""""""'""'".mw-parser-output .citation .cs1-lock-free abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .citation .cs1-lock-subscription abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registrationcolor:#555.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration spanborder-bottom:1px dotted;cursor:help.mw-parser-output .cs1-ws-icon abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png")no-repeat;background-position:right .1em center.mw-parser-output code.cs1-codecolor:inherit;background:inherit;border:inherit;padding:inherit.mw-parser-output .cs1-hidden-errordisplay:none;font-size:100%.mw-parser-output .cs1-visible-errorfont-size:100%.mw-parser-output .cs1-maintdisplay:none;color:#33aa33;margin-left:0.3em.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-formatfont-size:95%.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-leftpadding-left:0.2em.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-rightpadding-right:0.2em


  3. ^ ab Lee FY, Borzilleri R, Fairchild CR, et al. (December 2008). "Preclinical discovery of ixabepilone, a highly active antineoplastic agent". Cancer Chemother. Pharmacol. 63 (1): 157–66. doi:10.1007/s00280-008-0724-8. PMID 18347795.


  4. ^ Lopus, M; Smiyun, G; Miller, H; Oroudjev, E; Wilson, L; Jordan, MA (2015). "Mechanism of action of ixabepilone and its interactions with the βIII-tubulin isotype". Cancer Chemother Pharmacol. 76: 1013–24. doi:10.1007/s00280-015-2863-z. PMID 26416565.


  5. ^ Denduluri N, Swain SM (March 2008). "Ixabepilone for the treatment of solid tumors: a review of clinical data". Expert Opin Investig Drugs. 17 (3): 423–35. doi:10.1517/13543784.17.3.423. PMID 18321240.


  6. ^ Goodin S (November 2008). "Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer". Am J Health Syst Pharm. 65 (21): 2017–26. doi:10.2146/ajhp070628. PMID 18945860.


  7. ^ ab M. Vulfovich; Rocha-Lima, C; et al. (2008). "Novel advances in pancreatic cancer treatment". Expert Rev Anticancer Ther. 8 (6): 993–1002. doi:10.1586/14737140.8.6.993. PMID 18533808.


  8. ^ Medical News Today


  9. ^ London, 20 November 2008 Doc. Ref. EMEA/602569/2008


  10. ^ Thomas ES, Gomez HL, Li RK, et al. (November 2007). "Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment". J. Clin. Oncol. 25 (33): 5210–7. doi:10.1200/JCO.2007.12.6557. PMID 17968020.


  11. ^ Aghajanian C, Burris HA, Jones S, et al. (March 2007). "Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas". J. Clin. Oncol. 25 (9): 1082–8. doi:10.1200/JCO.2006.08.7304. PMID 17261851.



External links


  • Ixempra product website

  • Ixempra prescribing information

Ixabepilone
Ixabepilone.svg
Clinical data
Trade namesIxempra
SynonymsAzaepothilone B

AHFS/Drugs.com
Monograph
MedlinePlusa608042
License data


  • US FDA: Ixabepilone

Pregnancy
category


  • US: D (Evidence of risk)

Routes of
administration		Intravenous infusion
ATC code

  • L01DC04 (WHO)
Legal status
Legal status


  • US: ℞-only


Pharmacokinetic data
BioavailabilityN/A
Protein binding67 to 77%
MetabolismExtensive, hepatic, CYP3A4-mediated
Elimination half-life
52 hours
ExcretionFecal (mostly) and renal
Identifiers
CAS Number

  • 219989-84-1 ☒N

PubChem CID
  • 6445540
IUPHAR/BPS
  • 6824
DrugBank

  • DB04845 ☑Y
ChemSpider

  • 20145579 ☑Y
UNII
  • K27005NP0A
KEGG

  • D04645 ☑Y
ChEMBL

  • ChEMBL1201752 ☒N
ECHA InfoCard
100.158.736 Edit this at Wikidata
Chemical and physical data
Formula
C27H42N2O5S
Molar mass506.698 g/mol g·mol−1
3D model (JSmol)
  • Interactive image

.mw-parser-output .noboldfont-weight:normal
 ☒N☑Y (what is this?)
  (verify)














-

Popular posts from this blog

Lowndes Grove History Architecture References Navigation menu32°48′6″N 79°57′58″W / 32.80167°N 79.96611°W / 32.80167; -79.9661132°48′6″N 79°57′58″W / 32.80167°N 79.96611°W / 32.80167; -79.9661178002500"National Register Information System"Historic houses of South Carolina"Lowndes Grove""+32° 48' 6.00", −79° 57' 58.00""Lowndes Grove, Charleston County (260 St. Margaret St., Charleston)""Lowndes Grove"The Charleston ExpositionIt Happened in South Carolina"Lowndes Grove (House), Saint Margaret Street & Sixth Avenue, Charleston, Charleston County, SC(Photographs)"Plantations of the Carolina Low Countrye

Image
Contributing propertyKeeper of the RegisterHistoric districtHistory of the National Register of Historic PlacesNational Park ServiceProperty typesCharlestonColumbiaGreenvilleNorth CharlestonRock Hill Houses on the National Register of Historic Places in South CarolinaGeorgian architecture in South CarolinaHouses completed in 1786Plantation houses in South CarolinaNational Register of Historic Places in Charleston, South CarolinaHouses in Charleston, South Carolina plantation houseAshley RiverCharlestonNational Register of Historic PlacesRevolutionary WarWilliam LowndesU.S. CongressSouth Carolina Inter-State and West Indian ExpositionGeorgianDoricbalustradespedimentoculusentablaturemodilliondentillightship roofterra cottatilescorbelledcornicesRegency stylespiral staircaseskylight Lowndes Grove U.S. National Register of Historic Places Lowndes Grove in 1940 Show map of South Carolina Show map of the United States Location 260 St. Margaret St., Charleston, South Carolina Coordinates 32
Read more

random experiment with two different functions on unit interval Announcing the arrival of Valued Associate #679: Cesar Manara Planned maintenance scheduled April 23, 2019 at 00:00UTC (8:00pm US/Eastern)Random variable and probability space notionsRandom Walk with EdgesFinding functions where the increase over a random interval is Poisson distributedNumber of days until dayCan an observed event in fact be of zero probability?Unit random processmodels of coins and uniform distributionHow to get the number of successes given $n$ trials , probability $P$ and a random variable $X$Absorbing Markov chain in a computer. Is “almost every” turned into always convergence in computer executions?Stopped random walk is not uniformly integrable

Image
What would you call this weird metallic apparatus that allows you to lift people? Is it possible to give , in economics, an example of a relation ( set of ordered pairs) that is not a function? Maximum summed subsequences with non-adjacent items How many time has Arya actually used Needle? Is there public access to the Meteor Crater in Arizona? Belief In God or Knowledge Of God. Which is better? What is the meaning of 'breadth' in breadth first search? Why is there Net Work Done on a Pressure/Volume Cycle? How much damage would a cupful of neutron star matter do to the Earth? Sum letters are not two different Why does it sometimes sound good to play a grace note as a lead in to a note in a melody? What initially awakened the Balrog? How to pronounce 伝統色 QGIS virtual layer functionality does not seem to support memory layers AppleTVs create a chatty alternate WiFi network How to write capital alpha? How often does castling occur in grandmaster gam
Read more

How should I support this large drywall patch? Planned maintenance scheduled April 23, 2019 at 00:00UTC (8:00pm US/Eastern) Announcing the arrival of Valued Associate #679: Cesar Manara Unicorn Meta Zoo #1: Why another podcast?How do I cover large gaps in drywall?How do I keep drywall around a patch from crumbling?Can I glue a second layer of drywall?How to patch long strip on drywall?Large drywall patch: how to avoid bulging seams?Drywall Mesh Patch vs. Bulge? To remove or not to remove?How to fix this drywall job?Prep drywall before backsplashWhat's the best way to fix this horrible drywall patch job?Drywall patching using 3M Patch Plus Primer

Image
How do living politicians protect their readily obtainable signatures from misuse? Is it possible to force a specific program to remain in memory after closing it? File name problem(?) How to pronounce 伝統色 How does the math work when buying airline miles? Sum letters are not two different An adverb for when you're not exaggerating What does it mean that physics no longer uses mechanical models to describe phenomena? Take 2! Is this homebrew Lady of Pain warlock patron balanced? How many time has Arya actually used Needle? A letter with no particular backstory Converted a Scalar function to a TVF function for parallel execution-Still running in Serial mode Generate an RGB colour grid Co-worker has annoying ringtone Strange behavior of Object.defineProperty() in JavaScript "Lost his faith in humanity in the trenches of Verdun" — last line of an SF story What is this round thing on the pantry door in The Shining What would you call this weir
Read more